MedTrace Logo

Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.

NCT04512027 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-10-19

No results posted yet for this study

Summary

A randomised controlled trial of open label Prolectin-M; a (1-6)-alpha-D-Mannopyranose among patients with RT PCR positive COVID-19 patients.

Conditions

Interventions

OTHER

Prolectin-M; a (1-6)-alpha-D-Mannopyranose class

A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19

OTHER

Standard of Care

Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.

Sponsors & Collaborators

  • Bioxytran Inc.

    collaborator INDUSTRY

  • Composite Interceptive Med Science

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2020-09-19
Completion
2020-10-16

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04512027 on ClinicalTrials.gov